Human Milk Antibodies Elicited by BNT162b2 Vaccination have reduced activity against SARS-CoV-2 Variants of Concern

Objective

SARS-CoV-2 specific antibody responses are engendered in human milk after BNT162b2 vaccination.¹ However, the emergence of SARS-CoV-2 variants of concern (VOCs) raises questions about the specificity and potential cross-protection mediated by these antibodies. While antibody responses have been extensively studied for vaccinee sera,² human milk antibodies – a major contributor to passive immunity for infants – have not been analyzed.

Here, we investigated whether BNT162b2 vaccination induced secretion of specific immunoglobulin A (IgA) into human milk against the principal determinant of neutralization (Spike-receptor binding domain, RBD) for 4 major VOCs. These data illuminate our understanding of transferred mucosal immunity in lactating mothers receiving mRNA vaccines.

Study design

We conducted a prospective cohort study of lactating women. All received 2 doses of BNT162b2 (Pfizer/BioNTech) vaccine, given 21 days apart. Milk samples were collected pre-vaccination, 3-7 days after dose 2 (D2), and 4-6 weeks after D2. The study was approved by the Institutional Review Board (DSRB 2021/00095) and registered at ClinicalTrials.gov (NCT04802278); informed consent was obtained.

Enzyme-linked immunosorbent assay (ELISA) was used to assay IgA binding to SARS-CoV-2 RBD. IgA against Alpha (α, B.1.1.7), Beta (β, B.1.351), Gamma (γ, P.1), and Delta (δ, B.1.617.2) variants were tested using Kruskal-Wallis followed by Dunn’s Many-to-One Rank Comparison Test against the ancestral Wuhan-Hu-1 strain (WH-1). (See Supplemental Methods.)

Results

46 subjects (mean age 31.5 years, 13.5 months post-partum) completed the study (Supplementary Table). IgA antibodies against RBDs of WH-1 strain, and 4 major VOCs were found in milk within 3-7 days after D2. Compared to WH-1, RBD-specific IgA was significantly reduced by 28-33% for the Beta, Gamma and Delta variants at this timepoint (Figure 1A). No difference was detected for the Alpha variant.

• Download figure
• Open in new tab

Figure 1. Detection of IgA binding to receptor binding domain of SARS-CoV-2 spike proteins encoded by the ancestral Wuhan-Hu-1 strain and selected major VOCs.

Panel A, Differential human milk IgA binding to receptor binding domain (RBD) of SARS-CoV-2 spike protein of the ancestral Wuhan-Hu-1 strain (WH-1), Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2) variants of concern, after vaccination with BNT162b2 across 3 time points: pre-vaccination, 3-7 days post D2 and 4-6 weeks post D2. Each dot denotes an individual sample. Centre line denotes the median, and error bars show Quartile 1 (bottom bar) and Quartile 3 (top bar). P values were calculated using Dunn’s Many-to-One Rank Comparison Test and reported for VOC compared against WH-1. At 3-7 days post D2, reduction from WH-1 for Alpha = 8%, Beta = 28%, Gamma = 33%, Delta = 30%. At 4-6 weeks post D2, reduction from WH-1 for Alpha = 14%, Beta = 25%, Gamma = 30%, Delta = 25%.

Panel B, Kinetics of human milk IgA binding across 3 timepoints for ancestral Wuhan-Hu-1 strain (WH-1), Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2) variants of concern. Each line represents 1 strain. Dots represent the median and error bars represent interquartile range.

At 4-6 weeks after D2, milk IgA against WH-1 and all VOCs decreased but were still higher than the pre-vaccination baseline. IgA binding relative to WH-1 was reduced for all VOCs except Alpha, by 25-30% (Figure 1B).

Conclusion

We detected the presence of SARS-CoV-2 specific IgA against all major VOCs in milk out to 6 weeks after D2 of BNT162b2. These likely confer some protection to the breastfed infants, who are ineligible for vaccination and are at risk of severe COVID-19. ³

However, we detected significantly reduced milk IgA binding to VOCs, including the globally dominant Delta variant, suggesting reduced protection for breastfeeding infants. Additionally, these antibodies were significantly reduced by as early as 4-6 weeks after D2¹.

This study lends supports to the increasing importance of antenatal vaccination of pregnant women to facilitate transplacental transfer of IgG to the infant as it wanes slower at 5-6 months of life thereby augmenting both the magnitude and duration of passive immunity transferred from mother to child.⁴ Additionally, lactating mothers as a population could be prioritized for booster vaccine doses to maximize transferred immunity to vulnerable infants.

We acknowledge certain limitations of this study. No functional assays were performed; however, SARS-CoV-2 specific IgA binding in vaccinee milk has been positively correlated with neutralization.⁵ This is a small and relatively homogenous population; larger studies are warranted.

Supplemental methods

We conducted a prospective cohort study of a convenience sample of lactating women in Singapore. Participants were recruited between February 5-9, 2021 through advertisements. All received 2 doses of BNT162b2 (Pfizer/BioNTech) vaccine, with the second dose (D2) given 21 days after dose 1. Human milk samples were collected before administration of vaccine, 3-7 days after D2, and 4-6 weeks after D2. The study was approved by the Institutional Review Board (DSRB 2021/00095); informed consent was obtained. The study was registered at ClinicalTrials.gov (NCT04802278).

Milk samples were delipidated by centrifugation twice, at 10000g, 4 °C for 15 minutes each time. The clear portion was stored at -20 °C and thawed before use.

Receptor binding domain (RBD) of SARS-CoV-2 ancestral Wuhan-Hu-1 strain (WH-1), Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2) variants were diluted in PBS and coated on 384-well Maxisorp plates (NUNC) at 80 ng/well for overnight incubation at 4 °C. Plate was washed 3 times with 1x PBST buffer (0.05% Tween in 1x PBS) and blocked with 3% bovine serum albumin in 1x PBST for 1.5 hour incubation at room temperature. Delipidated milk was diluted 20-fold in the blocking buffer. After 3 plate washes in 1x PBST, diluted milk samples were added at 20 µL/well for 1 hour incubation at room temperature. Plate wash procedure was repeated thrice. Anti-human F(ab’)2 anti-human IgA-HRP (Invitrogen, #A24458) was diluted 5000-times in the blocking buffer and added to the plate at 20 µL/well for 1 hour incubation at room temperature, protected from light. After 3 plate washes in 1x PBST, 1-Step Ultra TMB-ELISA (Thermo Scientific, #34029) was added at 20 µL/well. Reaction was stopped with 20 µL/well 1 M H₂SO₄ 3 minutes later. OD₄₅₀ was measured using a microplate reader (Tecan Spark). Results were based on 3 technical replicates per sample.

Statistical analysis was performed with R (4.0.2) using the PMCMRPlus package (1.9.0). Tests performed were Kruskal-Wallis followed by Dunn’s Many-to-One Rank Comparison Test for comparisons of variants to WH-1